Kincell Bio Secures $22M to Expand Cell Therapy CDMO Capabilities

• Kincell Bio has completed a $22 million funding round led by NewSpring Capital and existing investor Kineticos Life Sciences.

• The funding will support cGMP expansion, process development services, and board-level leadership, including the appointment of Pete Buzy.

Kincell Bio, a cell therapy development and manufacturing company, has closed a $22 million funding round to accelerate its growth as a CDMO for advanced therapies. The investment was led by NewSpring Capital through its NewSpring Healthcare strategy, alongside continued support from existing backer Kineticos Life Sciences and other investors.

The funds will enable the company to expand its cGMP capabilities and process development services, targeting emerging cell therapy companies. The announcement also marks the appointment of Pete Buzy, former President and CEO of Catalent Cell & Gene Therapy, to Kincell Bio’s Board of Directors.

Mark R. Bamforth, CEO of Kincell Bio, said: “We are excited to partner with the experienced team at NewSpring… as we continue to scale our operations and deliver high-quality, flexible, and scalable solutions to our partners in the cell therapy space.”

Buzy, who has over 20 years of experience in advanced biologics and previously led Paragon Bioservices, brings strategic depth to Kincell Bio’s leadership. His background in contract manufacturing aligns with the company’s mission to serve innovators in the cell therapy space.

With the global cell and gene therapy market projected to exceed $23 billion by 2028, Kincell Bio’s investment positions the company for long-term growth in contract manufacturing. The company’s platform spans early clinical to commercial launch, offering customised, expert-driven services for complex therapies.